BAYN Stock Overview
Operates as a life science company worldwide. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 3/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Bayer Aktiengesellschaft Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €67.99 |
| 52 Week High | €0 |
| 52 Week Low | €0 |
| Beta | 1 |
| 11 Month Change | 0% |
| 3 Month Change | 0% |
| 1 Year Change | -66.01% |
| 33 Year Change | -66.01% |
| 5 Year Change | 0% |
| Change since IPO | 176.38% |
Recent News & Updates
Recent updates
Shareholder Returns
| BAYN | CH Pharmaceuticals | CH Market | |
|---|---|---|---|
| 7D | 0% | -3.0% | -1.4% |
| 1Y | -66.0% | 7.1% | 4.8% |
Return vs Industry: BAYN underperformed the Swiss Pharmaceuticals industry which returned 7.1% over the past year.
Return vs Market: BAYN underperformed the Swiss Market which returned 4.8% over the past year.
Price Volatility
| BAYN volatility | |
|---|---|
| BAYN Average Weekly Movement | n/a |
| Pharmaceuticals Industry Average Movement | 2.9% |
| Market Average Movement | 3.3% |
| 10% most volatile stocks in CH Market | 6.5% |
| 10% least volatile stocks in CH Market | 1.6% |
Stable Share Price: BAYN's share price has been volatile over the past 3 months compared to the Swiss market.
Volatility Over Time: Insufficient data to determine BAYN's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1863 | 94,245 | Bill Anderson | www.bayer.com |
Bayer Aktiengesellschaft operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women’s health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents, as well as cell and gene therapy.
Bayer Aktiengesellschaft Fundamentals Summary
| BAYN fundamental statistics | |
|---|---|
| Market cap | CHF 17.89b |
| Earnings (TTM) | -CHF 819.72m |
| Revenue (TTM) | CHF 43.54b |
0.4x
P/S Ratio-21.8x
P/E RatioIs BAYN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BAYN income statement (TTM) | |
|---|---|
| Revenue | €46.74b |
| Cost of Revenue | €20.03b |
| Gross Profit | €26.71b |
| Other Expenses | €27.59b |
| Earnings | -€880.00m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
Mar 05, 2025
| Earnings per share (EPS) | -0.90 |
| Gross Margin | 57.15% |
| Net Profit Margin | -1.88% |
| Debt/Equity Ratio | 134.1% |
How did BAYN perform over the long term?
See historical performance and comparison